

Haematologica  
HAEMATOL/2018/203885  
Version 4

A phase II study of the efficacy and safety of an intensified schedule of azacitidine in intermediate-2 and high risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des myelodysplasies (GFM)

Lionel Ades, Agnès Guerci-Bresler, Pascale Cony-Makhoul, Laurence Legros, Marie Sebert, Thosten Braun, Jacques Delaunay, Kristell Desseaux, Sylvie Chevret, and Pierre Fenaux  
Collaborative Groups: GROUPE FRANCOPHONE DES MYELOYDYSPLASIES)

Disclosures: The Groupe Francophone des Myélodysplasies was trial sponsor, and Celgene (Paris, France) provided a scientific grant, but was not involved in trial analysis or manuscript writing.

Contributions: LA, PF, KD, SC designed the study, analyzed the data and drafted the manuscript. LA, AG, PCM, LL, MS, TB, JD, PF enrolled the patients.